APO-CLOZAPINE PRODUCT LAUNCH

When Apotex Inc. launched Apo-Clozapine an atypical antipsychotic drug indicated for the management of symptoms in treatment-resistant schizophrenia, they required Maximum 60 to design a physician/pharmacist education tool to ensure them that Apo-Clozapine was bioequivalent to the brand alternative. As well, the campaign introduced the Apo-Clozapine Risk Management Program – a vital monitoring system mandated by Health Canada as a patient monitoring system to ensure the optimal safety of all patients using the drug.